Fracture healing with alendronate treatment in the Brtl/ plus mouse model of osteogenesis imperfecta

被引:19
|
作者
Meganck, J. A. [1 ,2 ]
Begun, D. L. [1 ,2 ]
McElderry, J. D. [3 ]
Swick, A. [1 ,2 ]
Kozloff, K. M. [1 ,2 ]
Goldstein, S. A. [1 ,2 ]
Morris, M. D. [3 ]
Marini, J. C. [4 ]
Caird, M. S. [1 ]
机构
[1] Univ Michigan, Dept Orthopaed Surg, Orthopaed Res Labs, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA
[4] NICHHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
Osteogenesis imperfecta; Bisphosphonates; Bone; Rodent; Fracture repair; HYPERPLASTIC CALLUS FORMATION; POLARIZED-LIGHT MICROSCOPY; ZOLEDRONIC ACID; BISPHOSPHONATE INCADRONATE; BONE STRENGTH; CHILDREN; PAMIDRONATE; COLLAGEN; REPAIR; RATS;
D O I
10.1016/j.bone.2013.06.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteogenesis imperfecta (OI) is a heritable bone dysplasia characterized by increased skeletal fragility. Patients are often treated with bisphosphonates to attempt to reduce fracture risk. However, bisphosphonates reside in the skeleton for many years and long-term administration may impact bone material quality. Acutely, there is concern about risk of non-union of fractures that occur near the time of bisphosphonate administration. This study investigated the effect of alendronate, a potent aminobisphosphonate, on fracture healing. Using the Brtl/+ murine model of type IV OI, tibial fractures were generated in 8-week-old mice that were untreated, treated with alendronate before fracture, or treated before and after fracture. After 2, 3, or 5 weeks of healing, tibiae were assessed using microcomputed tomography (mu CT), torsion testing, quantitative histomorphometry, and Raman microspectroscopy. There were no morphologic, biomechanical or histomorphometric differences in callus between untreated mice and mice that received alendronate before fracture. Alendronate treatment before fracture did not cause a significant increase in cartilage retention in fracture callus. Both Brtl/+ and WT mice that received alendronate before and after fracture had increases in the callus volume, bone volume fraction and torque at failure after 5 weeks of healing. Raman microspectroscopy results did not show any effects of alendronate in wild-type mice, but calluses from Brtl+ mice treated with alendronate during healing had a decreased mineral-to-matrix ratio, decreased crystallinity and an increased carbonate-to-phosphate ratio. Treatment with alendronate altered the dynamics of healing by preventing callus volume decreases later in the healing process. Fracture healing in Brtl/+ untreated animals was not significantly different from animals in which alendronate was halted at the time of fracture. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:204 / 212
页数:9
相关论文
共 50 条
  • [21] Metabolic phenotype in the mouse model of osteogenesis imperfecta
    Boraschi-Diaz, Iris
    Tauer, Josephine T.
    El-Rifai, Omar
    Guillemette, Delphine
    Lefebvre, Genevieve
    Rauch, Frank
    Ferron, Mathieu
    Komarova, Svetlana V.
    JOURNAL OF ENDOCRINOLOGY, 2017, 234 (03) : 279 - 289
  • [22] Fracture Healing in Collagen-Related Preclinical Models of Osteogenesis Imperfecta
    Zieba, Jennifer
    Munivez, Elda
    Castellon, Alexis
    Jiang, Ming-Ming
    Dawson, Brian
    Ambrose, Catherine G.
    Lee, Brendan
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 (06) : 1132 - 1148
  • [23] Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength
    Sinder, B. P.
    White, L. E.
    Salemi, J. D.
    Ominsky, M. S.
    Caird, M. S.
    Marini, J. C.
    Kozloff, K. M.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 (08) : 2097 - 2107
  • [24] Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength
    B. P. Sinder
    L. E. White
    J. D. Salemi
    M. S. Ominsky
    M. S. Caird
    J. C. Marini
    K. M. Kozloff
    Osteoporosis International, 2014, 25 : 2097 - 2107
  • [25] RANKL Inhibition Improves Bone Properties in a Mouse Model of Osteogenesis Imperfecta
    Bargman, Renee
    Huang, Alice
    Boskey, Adele L.
    Raggio, Cathleen
    Pleshko, Nancy
    CONNECTIVE TISSUE RESEARCH, 2010, 51 (02) : 123 - 131
  • [26] Pathological mandibular fracture after simple molar extraction in a patient with osteogenesis imperfecta treated with alendronate
    Gallego, Lorena
    Junquera, Luis
    Pelaz, Alejandro
    Costilla, Serafin
    MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2010, 15 (06): : E895 - E897
  • [27] Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse
    Misof, BM
    Roschger, P
    Baldini, T
    Raggio, CL
    Zraick, V
    Root, L
    Boskey, AL
    Klaushofer, K
    Fratzl, P
    Carnacho, NP
    BONE, 2005, 36 (01) : 150 - 158
  • [28] Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta
    Roschger, Andreas
    Roschger, Paul
    Keplingter, Petra
    Klaushofer, Klaus
    Abdullah, Sami
    Kneissel, Michaela
    Rauch, Frank
    BONE, 2014, 66 : 182 - 188
  • [29] Fecundity is impaired in a mouse model of osteogenesis imperfecta
    Oestreich, Arin K.
    DeCata, Jenna A.
    Akers, Janae D.
    Phillips, Charlotte L.
    Schulz, Laura. C.
    MOLECULAR REPRODUCTION AND DEVELOPMENT, 2020, 87 (09) : 927 - 929
  • [30] Effect of Anti-TGF-β Treatment in a Mouse Model of Severe Osteogenesis Imperfecta
    Tauer, Josephine T.
    Abdullah, Sami
    Rauch, Frank
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (02) : 207 - 214